education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Iklan
Iklan
MIMS home
Drugs
Info
Simnos
Simnos
Manufacturer:
Simex
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Per 5 mL
Pseudoephedrine HCl 15 mg, chlorpheniramine maleate 1 mg
Indications/Uses
Symptomatic relief of sneezing & nasal congestion caused by cold.
Dosage/Direction for Use
Adult & childn >12 yr
10 mL 3 times daily.
Childn 2-5 yr
2.5 mL 3 times daily.
Contraindications
Hypersensitivity.
Special Precautions
Glaucoma, prostate hypertrophy, hyperthyroid, urinary retention, heart diseases, DM. Concomitant use w/ other CNS depressants. May impair the ability to drive the vehicle or operate the machinery. Patients w/ impaired liver & kidney function. Pregnancy & lactation. Childn < 2 yr.
Adverse Reactions
Insomnia, headache, excitation, tremor, tachycardia, arrhythmia, palpitation, difficulty in micturition, drowsiness, dry mouth.
View
ADR Reporting Link
Drug Interactions
MAOIs, sympathomimetic agents, antidepressants.
MIMS Class
Cough & Cold Preparations
ATC Classification
R01BA52 - pseudoephedrine, combinations ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
Regulatory Classification
T
Presentation/Packing
Form
Simnos syr
Packing/Price
60 mL x 1's (Rp30,000/boks)
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Iklan
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk